logo
logo

Engine Biosciences Announces $43 Million Series A Round To Decipher Genetic Codes For New Medicines Through Machine Learning And Next-Generation Combinatorial Genetics

May 26, 2021•over 4 years ago

Amount Raised

$43 Million

Round Type

series a

Description

Engine Biosciences (“Engine”) today announced the successful completion of an oversubscribed $43 million Series A funding round. Engine identifies errors in the complex genetic codes of diseases, fixing them with precise therapeutic solutions. This round was led by Polaris Partners and also included new investors Invus and one of the world’s premier institutional investors, based in Singapore. Existing investors also participated in the Series A, which included 6 Dimensions Capital, WuXi AppTec, DHVC, EDBI, Baidu Ventures, Vectr Ventures, Goodman Capital, WI Harper, and Nest.Bio

Company Information

Company

Engine Biosciences

About

Engine Biosciences is a venture-backed Singapore- and Silicon Valley-based company deciphering complex biology to unleash many impactful medicines. Our proprietary NetMAPPR platform integrates data science and machine learning, high-throughput biological experiments using our patented CombiGEM combinatorial genetics system, computational and wet lab chemistry, and drug discovery. We systematically analyze biological networks comprising millions-to-billions of gene interactions at greater speed and scale than conventionally possible, yielding promising drug targets for specific patient populations. Led by drug discovery and technology industry veterans and scientific pioneers, we are developing our growing pipeline of precision oncology therapeutics and working with partners to expand our impact. For more information, please visit www.enginebio.com

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech